Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis

Brennan, Amanda; Gyi, Khin M.; Wood, David; Johnson, Julie; Holliman, R. E.; Baines, Deborah L.; Philips, Barbara J.; Geddes, Duncan M.; Hodson, Margaret E.; Baker, Emma H.

doi:10.1016/j.jcf.2006.03.009

Cited by 178 publications

(155 citation statements)

References 32 publications

(52 reference statements)

Supporting

Mentioning

147

Contrasting

Unclassified

Order By: Relevance

“…Nutritional condition and pulmonary function begin to deteriorate several years prior CFRD diagnosis, a period in which minimal hyperglycemia is present (9,11). Modest increases in glycemia (≥ 144 mg/dL) may influence pulmonary function, as they promote a glycemic increase in the bronchial tree, which may facilitate the growth of respiratory pathogens (47). Fasting hyperglycemia (FH) does not appear to be relevant in the progression of the disease, as there was no difference in pulmonary function and nutritional condition among CFRD patients with and without FH (7).…”

Section: Pathophysiology Of Cfrdmentioning

confidence: 99%

Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD)

Noronha

Calliari

Damaceno

et al. 2011

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Cystic fibrosis (CF) is the most common recessive autosomal disease among Caucasian. Children with CF have benefitted from advances in medical and nutritional treatments, and this can be gleaned from the improvement in the survival of these patients. The increase in the survival rate brought with it the appearance of co-morbidities related to CF. Nowadays cystic fibrosis-related diabetes (CFRD) is considered the most common complication associated with CF. It can appear as early as infancy or adolescence, and its prevalence can be as high as 50% in adult patients. Because of its high prevalence, difficulties in early detection and the risks involved, in recent years several studies and consensuses have focused on this condition, adding information about the epidemiology, pathophysiology, prognosis and treatment of CFRD. The main aspects of these new concepts, as well as the current recommendations for its diagnosis and follow-up, will be presented in this study.

show abstract

Section: Pathophysiology Of Cfrdmentioning

confidence: 99%

Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD)

Noronha

Calliari

Damaceno

et al. 2011

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…Diabetes has been directly implicated in the pathophysiology of CF lung function decline, related to both the catabolic effect of insulin insufficiency on nutritional status and muscle mass (6)(7)(8)(9)(10) and the proinflammatory, proinfection impact of chronic hyperglycemia on lung function (11,12).…”

mentioning

confidence: 99%

Diabetes-related Mortality in Adults with Cystic Fibrosis. Role of Genotype and Sex

Lewis

Blackman

Nelson

et al. 2015

Am J Respir Crit Care Med

161

124

View full text Add to dashboard Cite

Rationale: Diabetes is associated with increased mortality in cystic fibrosis. Aggressive screening and early institution of insulin treatment significantly reduced this risk over the period of 1992-2008.Objectives: To determine if progressive improvement in cystic fibrosis-related diabetes (CFRD) mortality has continued since 2008, and examine associations with CFTR genotypes linked to pancreatic insufficiency and to sex.Methods: Chart review was performed on 664 patients followed from 2008 to 2012. Measurements and Main Results:Overall mortality for patients with CFRD was 1.8 per 100 person-years, compared with 0.5 in patients with CF without diabetes (P = 0.0002); neither rate changed significantly from mortality reported for [2003][2004][2005][2006][2007][2008]. Genotype impacted both mortality and diabetes risk: adults with severe CFTR genotypes experienced greater mortality at every age older than 32 years than those with mild genotypes (P = 0.002), and the risk of developing CFRD was also greatly increased in those with severe genotypes (prevalence 60% in adult patients with severe vs. 14% in adults with mild mutations). CFRD had a direct influence on mortality because it was associated with increased risk of death within each genotype category (20 vs. 2%, P = 0.007 for mild; 12 vs. 4%, P = 0.012 for severe). There was also a sex difference in adults with severe CFTR genotypes; both mortality and CFRD prevalence were higher at every age in females than males.Conclusions: Despite substantial improvement over time, mortality for CFRD patients greater than 30 years remains higher than for patients with CF without diabetes.

show abstract

“…In a study published in 2007, Brennan et al 133 compared BG and airway secretion glucose (using nasal secretions), but added studies of the growth rates of S. aureus and P. aeruginosa. They found that glucose was present in airway secretions in 85% of cases when BG levels were > 8 mmol/l, but in only 19% (but none with high airway glucose) when it was < 8 mmol/l.…”

mentioning

confidence: 99%

Screening for cystic fibrosis-related diabetes: a systematic review.

Waugh

Royle²,

Craigie³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects...

show abstract

Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis

Cited by 178 publications

References 32 publications

Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD)

Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD)

Diabetes-related Mortality in Adults with Cystic Fibrosis. Role of Genotype and Sex

Screening for cystic fibrosis-related diabetes: a systematic review.

Contact Info

Product

Resources

About